CryoLife Inc. (NYSE:CRY) shares dropped 2% during mid-day trading on Tuesday . The stock traded as low as $15.88 and last traded at $16.06, with a volume of 239,105 shares traded. The stock had previously closed at $16.39.

CRY has been the subject of several research reports. Lake Street Capital initiated coverage on CryoLife in a research report on Wednesday, June 15th. They set a “buy” rating and a $15.00 price objective for the company. Canaccord Genuity reiterated a “buy” rating on shares of CryoLife in a report on Monday, June 20th. Zacks Investment Research downgraded CryoLife from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 5th. Finally, Piper Jaffray Cos. reiterated an “overweight” rating and issued a $16.00 price target on shares of CryoLife in a report on Wednesday, July 27th. One analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $15.00.

The company has a 50 day moving average price of $14.21 and a 200-day moving average price of $12.18. The stock has a market capitalization of $547.81 million and a price-to-earnings ratio of 51.47.

CryoLife (NYSE:CRY) last posted its quarterly earnings data on Monday, July 25th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.11. The company earned $47.10 million during the quarter, compared to the consensus estimate of $35.50 million. The company’s revenue was up 32.6% on a year-over-year basis. During the same quarter last year, the business earned $0.03 earnings per share. Analysts predict that CryoLife Inc. will post $0.24 earnings per share for the current year.

In other news, Director C Elkins Ronald sold 2,000 shares of the stock in a transaction that occurred on Tuesday, July 26th. The shares were sold at an average price of $14.00, for a total value of $28,000.00. Following the completion of the transaction, the director now directly owns 103,586 shares in the company, valued at $1,450,204. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

CryoLife, Inc (CryoLife) is engaged in medical device manufacturing and distribution, and in the processing and distribution of implantable human tissues for cardiac and vascular surgeries. The Company operates in two segments: Medical Devices and Preservation Services. The Medical Devices segment sells BioGlue, BioFoam, PerClot, CardioGenesis cardiac laser therapy, Hemodialysis Reliable Outflow (HeRO) Graft, and ProCol Vascular Bioprosthesis (ProCol).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.